Virtus Investment Advisers Inc. Purchases Shares of 13,950 SI-BONE, Inc. (NASDAQ:SIBN)

Virtus Investment Advisers Inc. acquired a new stake in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,950 shares of the company's stock, valued at approximately $196,000.

A number of other institutional investors have also modified their holdings of SIBN. Silvercrest Asset Management Group LLC grew its position in shares of SI-BONE by 21.9% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company's stock valued at $27,392,000 after buying an additional 350,970 shares during the last quarter. American Century Companies Inc. boosted its stake in SI-BONE by 11.0% during the 4th quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock valued at $33,341,000 after purchasing an additional 236,167 shares during the period. Marshall Wace LLP lifted its stake in shares of SI-BONE by 332.5% in the 4th quarter. Marshall Wace LLP now owns 264,523 shares of the company's stock worth $3,709,000 after acquiring an additional 203,361 shares during the period. Nuveen Asset Management LLC lifted its stake in shares of SI-BONE by 17.8% in the 4th quarter. Nuveen Asset Management LLC now owns 1,263,988 shares of the company's stock worth $17,721,000 after acquiring an additional 190,830 shares during the period. Finally, First Eagle Investment Management LLC acquired a new stake in shares of SI-BONE in the 4th quarter worth approximately $2,600,000. Institutional investors own 98.11% of the company's stock.

SI-BONE Stock Down 3.7%

SI-BONE stock traded down $0.70 during trading hours on Thursday, hitting $18.42. The company had a trading volume of 288,709 shares, compared to its average volume of 375,002. The firm has a market capitalization of $784.97 million, a P/E ratio of -20.02 and a beta of 0.82. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The firm's fifty day moving average is $15.11 and its 200-day moving average is $15.14. SI-BONE, Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $20.05.

SI-BONE (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $47.29 million for the quarter, compared to analyst estimates of $45.13 million. On average, research analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Anshul Maheshwari sold 4,937 shares of the company's stock in a transaction on Wednesday, May 7th. The shares were sold at an average price of $17.00, for a total transaction of $83,929.00. Following the completion of the sale, the chief financial officer now directly owns 265,356 shares of the company's stock, valued at approximately $4,511,052. This represents a 1.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Laura Francis sold 38,504 shares of the company's stock in a transaction on Wednesday, May 7th. The stock was sold at an average price of $17.18, for a total transaction of $661,498.72. Following the sale, the chief executive officer now directly owns 302,958 shares of the company's stock, valued at approximately $5,204,818.44. This represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 92,565 shares of company stock valued at $1,669,871. Company insiders own 4.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on SIBN shares. Truist Financial upped their price target on shares of SI-BONE from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. Needham & Company LLC reissued a "buy" rating and set a $24.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.